These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 17726715

  • 1. Blinded sample size reestimation in non-inferiority trials with binary endpoints.
    Friede T, Mitchell C, Müller-Velten G.
    Biom J; 2007 Dec; 49(6):903-16. PubMed ID: 17726715
    [Abstract] [Full Text] [Related]

  • 2. Blinded sample size reassessment in non-inferiority and equivalence trials.
    Friede T, Kieser M.
    Stat Med; 2003 Mar 30; 22(6):995-1007. PubMed ID: 12627414
    [Abstract] [Full Text] [Related]

  • 3. Blinded sample size recalculation in multicentre trials with normally distributed outcome.
    Jensen K, Kieser M.
    Biom J; 2010 Jun 30; 52(3):377-99. PubMed ID: 20394080
    [Abstract] [Full Text] [Related]

  • 4. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis.
    Friede T, Schmidli H.
    Stat Med; 2010 May 10; 29(10):1145-56. PubMed ID: 20146203
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Large sample tests for binary outcomes in fixed-dose combination drug studies.
    Wang SJ, Hung HM.
    Biometrics; 1997 Jun 10; 53(2):498-503. PubMed ID: 9192448
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
    Friede T, Kieser M.
    Pharm Stat; 2011 Jun 10; 10(1):8-13. PubMed ID: 19943322
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
    Vaucher P.
    Vaccine; 2009 Mar 18; 27(13):1928-31. PubMed ID: 19368773
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Design of adaptive two-stage double-arm clinical trials for dichotomous variables.
    Jiang Z, Xue F, Li C, Wang L, Cai H, Zhang C, Xia J.
    Contemp Clin Trials; 2010 May 18; 31(3):242-50. PubMed ID: 20172053
    [Abstract] [Full Text] [Related]

  • 18. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.
    Lai TL, Shih MC, Zhu G.
    Stat Med; 2006 Apr 15; 25(7):1149-67. PubMed ID: 16189814
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Simple procedures for blinded sample size adjustment that do not affect the type I error rate.
    Kieser M, Friede T.
    Stat Med; 2003 Dec 15; 22(23):3571-81. PubMed ID: 14652861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.